Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.

Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y

The lancet. Diabetes & endocrinology30 Jul 2022Cited by 101 (Europe PMC)

PMID35914542DOI10.1016/s2213-8587(22)00187-5PepBankPUB-35914542

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

01HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes on oral monotherapy, most participants had at least one treatment-emergent adverse event with tirzepatide.
In plain wordsIn Japanese adults with type 2 diabetes, most people taking tirzepatide had at least one side effect during treatment.
Peptide
Tirzepatide
Outcome
Not applicableAny treatment-emergent adverse event
Study
n = 443
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
5, 10 or 15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with at least one TEAE
343 participants
tirzepatide, all doses
Source sentences
Summary
Most participants (343 [77%] of 443) had at least one treatment-emergent adverse event.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454201
02HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, treatment-emergent adverse events occurred in 109 of 148 participants on tirzepatide 5 mg.
In plain wordsIn Japanese adults with type 2 diabetes, 109 of 148 people on tirzepatide 5 mg had a side effect during treatment.
Peptide
Tirzepatide
Outcome
Not applicableTreatment-emergent adverse events, 5 mg
Study
n = 148
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
5 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with TEAE
109 participants
5 mg
Source sentences
Summary
Treatment-emergent adverse events were more frequent in the tirzepatide 15 mg group (125 [84%] of 148) than the 5 mg (109 [74%] of 148) and 10 mg groups (109 [74%] of 147).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454202
03HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, treatment-emergent adverse events were more frequent with tirzepatide 15 mg than with 5 mg and 10 mg.
In plain wordsIn Japanese adults with type 2 diabetes, side effects were more common on tirzepatide 15 mg than on 5 mg or 10 mg.
Peptide
Tirzepatide
Outcome
IncreaseTreatment-emergent adverse events, 15 mg
Study
n = 148
Comparator
Tirzepatide 5 mg and 10 mg
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with TEAE
125 participants
15 mg
Source sentences
Summary
Treatment-emergent adverse events were more frequent in the tirzepatide 15 mg group (125 [84%] of 148) than the 5 mg (109 [74%] of 148) and 10 mg groups (109 [74%] of 147).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454204
04HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, treatment-emergent adverse events occurred in 109 of 147 participants on tirzepatide 10 mg.
In plain wordsIn Japanese adults with type 2 diabetes, 109 of 147 people on tirzepatide 10 mg had a side effect during treatment.
Peptide
Tirzepatide
Outcome
Not applicableTreatment-emergent adverse events, 10 mg
Study
n = 147
Analysis
Primary
Outcome group
Adverse events · Whole body
Studied dose
10 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with TEAE
109 participants
10 mg
Source sentences
Summary
Treatment-emergent adverse events were more frequent in the tirzepatide 15 mg group (125 [84%] of 148) than the 5 mg (109 [74%] of 148) and 10 mg groups (109 [74%] of 147).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454203
05HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, mild or moderate nasopharyngitis was among the most frequent adverse events with tirzepatide.
In plain wordsIn Japanese adults with type 2 diabetes, mild or moderate nasopharyngitis was a common side effect of tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableNasopharyngitis
Study
n = 443
Outcome group
Adverse events · Infection
Studied dose
5, 10 or 15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with nasopharyngitis
75 participants
tirzepatide, all doses
Source sentences
Summary
The most frequent treatment-emergent adverse events with tirzepatide were mild or moderate nasopharyngitis (75 [17%]), nausea (74 [17%]), constipation (54 [12%]), diarrhoea (51 [12%]), and decreased appetite (44 [10%]).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454205
06HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, mild or moderate nausea was among the most frequent adverse events with tirzepatide.
In plain wordsIn Japanese adults with type 2 diabetes, mild or moderate nausea was a common side effect of tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableNausea
Study
n = 443
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 or 15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with nausea
74 participants
tirzepatide, all doses
Source sentences
Summary
The most frequent treatment-emergent adverse events with tirzepatide were mild or moderate nasopharyngitis (75 [17%]), nausea (74 [17%]), constipation (54 [12%]), diarrhoea (51 [12%]), and decreased appetite (44 [10%]).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454206
07HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, mild or moderate constipation was among the most frequent adverse events with tirzepatide.
In plain wordsIn Japanese adults with type 2 diabetes, mild or moderate constipation was a common side effect of tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableConstipation
Study
n = 443
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 or 15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with constipation
54 participants
tirzepatide, all doses
Source sentences
Summary
The most frequent treatment-emergent adverse events with tirzepatide were mild or moderate nasopharyngitis (75 [17%]), nausea (74 [17%]), constipation (54 [12%]), diarrhoea (51 [12%]), and decreased appetite (44 [10%]).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454207
08HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, mild or moderate diarrhoea was among the most frequent adverse events with tirzepatide.
In plain wordsIn Japanese adults with type 2 diabetes, mild or moderate diarrhoea was a common side effect of tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableDiarrhoea
Study
n = 443
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5, 10 or 15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with diarrhoea
51 participants
tirzepatide, all doses
Source sentences
Summary
The most frequent treatment-emergent adverse events with tirzepatide were mild or moderate nasopharyngitis (75 [17%]), nausea (74 [17%]), constipation (54 [12%]), diarrhoea (51 [12%]), and decreased appetite (44 [10%]).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454208
09HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, mild or moderate decreased appetite was among the most frequent adverse events with tirzepatide.
In plain wordsIn Japanese adults with type 2 diabetes, mild or moderate loss of appetite was a common side effect of tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableDecreased appetite
Study
n = 443
Outcome group
Appetite and food intake · Gastrointestinal
Studied dose
5, 10 or 15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants with decreased appetite
44 participants
tirzepatide, all doses
Source sentences
Summary
The most frequent treatment-emergent adverse events with tirzepatide were mild or moderate nasopharyngitis (75 [17%]), nausea (74 [17%]), constipation (54 [12%]), diarrhoea (51 [12%]), and decreased appetite (44 [10%]).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454209
10HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, 398 of 443 participants (90%) completed the study and treatment with tirzepatide.
In plain wordsIn Japanese adults with type 2 diabetes, 398 of 443 people (90%) finished the study and treatment with tirzepatide.
Peptide
Tirzepatide
Outcome
Not applicableStudy completion
Study
n = 443
Outcome group
Adverse events · Whole body
Studied dose
5, 10 or 15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Participants completing study and treatment
398 participants
tirzepatide, all doses
Source sentences
Summary
398 (90%) participants completed the study and treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454210
11HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, no adjudication-confirmed deaths were reported with tirzepatide.
In plain wordsIn Japanese adults with type 2 diabetes, no deaths confirmed by adjudication were reported during tirzepatide treatment.
Peptide
Tirzepatide
Outcome
No significant changeDeaths
Study
n = 443
Outcome group
Mortality · Whole body
Studied dose
5, 10 or 15 mg · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
No adjudication-confirmed deaths were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454211
12HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, body weight fell from baseline with tirzepatide 5 mg at week 52.
In plain wordsIn Japanese adults with type 2 diabetes, tirzepatide 5 mg reduced body weight from baseline after 52 weeks.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change at week 52, 5 mg
Study
n = 148
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Mean change in body weight
−3.8 kg
5 mg
Mean change in body weight
−5.1%
5 mg
Source sentences
Summary
At week 52, mean changes from baseline in bodyweight were -3·8 kg (SE 0·5; -5·1% reduction) in the 5 mg group, -7·5 kg (0·5; -10·1% reduction) in the 10 mg group, and -10·2 kg (0·5; -13·2% reduction) in the 15 mg group.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454212
13HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, body weight fell from baseline with tirzepatide 15 mg at week 52.
In plain wordsIn Japanese adults with type 2 diabetes, tirzepatide 15 mg reduced body weight from baseline after 52 weeks.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change at week 52, 15 mg
Study
n = 148
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Mean change in body weight
−10.2 kg
15 mg
Mean change in body weight
−13.2%
15 mg
Source sentences
Summary
At week 52, mean changes from baseline in bodyweight were -3·8 kg (SE 0·5; -5·1% reduction) in the 5 mg group, -7·5 kg (0·5; -10·1% reduction) in the 10 mg group, and -10·2 kg (0·5; -13·2% reduction) in the 15 mg group.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454214
14HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, HbA1c fell from baseline with tirzepatide 5 mg at week 52.
In plain wordsIn Japanese adults with type 2 diabetes, tirzepatide 5 mg lowered HbA1c from baseline after 52 weeks.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c at week 52, 5 mg
Study
n = 148
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
LS mean HbA1c baseline
8.5%
5 mg
LS mean HbA1c week 52
6%
5 mg
Source sentences
Summary
Least squares mean HbA_1c at baseline reduced from 8·5% (SE 0·1) to 6·0% (0·1) in the 5 mg tirzepatide group, from 8·6% (0·1) to 5·6% (0·1) in the 10 mg group, and from 8·6% (0·1) to 5·6% (0·1) in the 15 mg group at week 52.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454215
15HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, HbA1c fell from baseline with tirzepatide 15 mg at week 52.
In plain wordsIn Japanese adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c from baseline after 52 weeks.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c at week 52, 15 mg
Study
n = 148
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
LS mean HbA1c baseline
8.6%
15 mg
LS mean HbA1c week 52
5.6%
15 mg
Source sentences
Summary
Least squares mean HbA_1c at baseline reduced from 8·5% (SE 0·1) to 6·0% (0·1) in the 5 mg tirzepatide group, from 8·6% (0·1) to 5·6% (0·1) in the 10 mg group, and from 8·6% (0·1) to 5·6% (0·1) in the 15 mg group at week 52.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454217
16HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, body weight fell from baseline with tirzepatide 10 mg at week 52.
In plain wordsIn Japanese adults with type 2 diabetes, tirzepatide 10 mg reduced body weight from baseline after 52 weeks.
Peptide
Tirzepatide
Outcome
DecreaseBody weight change at week 52, 10 mg
Study
n = 147
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Mean change in body weight
−7.5 kg
10 mg
Mean change in body weight
−10.1%
10 mg
Source sentences
Summary
At week 52, mean changes from baseline in bodyweight were -3·8 kg (SE 0·5; -5·1% reduction) in the 5 mg group, -7·5 kg (0·5; -10·1% reduction) in the 10 mg group, and -10·2 kg (0·5; -13·2% reduction) in the 15 mg group.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454213
17HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, HbA1c fell from baseline with tirzepatide 10 mg at week 52.
In plain wordsIn Japanese adults with type 2 diabetes, tirzepatide 10 mg lowered HbA1c from baseline after 52 weeks.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c at week 52, 10 mg
Study
n = 147
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
LS mean HbA1c baseline
8.6%
10 mg
LS mean HbA1c week 52
5.6%
10 mg
Source sentences
Summary
Least squares mean HbA_1c at baseline reduced from 8·5% (SE 0·1) to 6·0% (0·1) in the 5 mg tirzepatide group, from 8·6% (0·1) to 5·6% (0·1) in the 10 mg group, and from 8·6% (0·1) to 5·6% (0·1) in the 15 mg group at week 52.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, open-label, parallel-group, randomised, phase 3 trial was conducted at 34 medical research centres and hospitals in Japan.
Summary · context
After a 2-week screening and 2-week lead-in period, all participants were randomly assigned (1:1:1) to receive 5, 10, or 15 mg of tirzepatide, administered once per week subcutaneously for 52 weeks followed by a 4 week safety follow-up period, using a computer-generated random sequence and interacti…
Report a problemFND-3591454216

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03861039

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 44330 Mar 2019 to 16 Feb 2021

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 14 Feb 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.